ABOUT US

Company Overview

ARBO Biotechnology Limited is a company dedicated to advancing the field of biotechnology through its scientific research and development projects. With a strong focus on innovation, ARBO is committed to advancing healthcare through the development of new generation vaccine formulations, diagnostic kits, drugs and personalized medicine approaches. Its extensive research efforts encompass a wide range of diseases affecting both humans and animals. Through rigorous scientific studies and experiments, ARBO Biotechnology Limited aims to revolutionize the healthcare industry by introducing new generation vaccine adjuvants that are more efficient, safe, and effective.

Alongside its vaccine development endeavors, the company also places significant emphasis on the development of diagnostic kits that enable quick and accurate detection of diseases such as prostate cancer diagnosis kit by using extracellular vesicles and ELISA & Flow Cytometry Diagnostic Kits for diagnosis of COVID-19.

With a strong focus on personalized medicine, the company is also dedicated to finding innovative approaches for treating various diseases, particularly cancer. One of the key areas of research at ARBO Biotechnology Limited involves the use of tumor extracellular vesicles. These tiny vesicles, released by cancer cells, contain valuable information about the disease and can be extracted and utilized to develop targeted therapies. This personalized approach allows for the development of highly tailored treatment plans that address the specific needs of each patient, improving the efficacy and outcomes of cancer treatments.

OUR PROJECTS

2013 - Use of Various TLR Agonists as Adjuvants in improving Food & Mouth Disease Efficacy, Supported by the Ministry of Science, Industry and Technology, Techno-initiative Fund.

2014 - Use of CpG ODN’s as adjuvants in Avian Salmonella vaccine formulations. Supported by the Ministry of Science, Industry and Technology, Techno-initiative Fund.

2014 - Development of adjuvants for use in increasing vaccine efficacy.

2014 - Development of prostate cancer detection kits using extracellular vesicles in urine. Funded by the 1512 Entrepreneurial Support Program.

2017 - Nucleic acid based protective and therapeutic Hepatits B vaccine.

2019 - Personalized exosome based therapeutic cancer vaccine.

2021 - Development of ELISA & Flow Cytometry Diagnostic Kits for COVID-19. Funded by the Turkish FDA 1501 Coded Industry R&D Support Program.

2023 - Development of Cytokine and Kemokine pre-coated ELISA plates for Research.

1. Yazar V, Kilic G, Bulut O, Yildirim Canavar T, Yagci FC, Aykut G, Klinman DM, Gursel M, Gursel I. “A suppressive oligodeoxynucleotide expressing TTAGGG motifs modulates cellular energetics through the mTOR signaling pathway”. Int Immunol. October 2019.

2. Kahraman T, Gucluler G, Simsek I, Yagci FC, Yildirim M, Ozen C, Dinc A, Gursel M, Ikromzoda L, Sutlu T, Gay S, Gursel I. “ Circulating LL37 targets plasma extracellular vesicles to immune cells and intensifies Behcet’s disease severity”. J Extracell Vesicles 28;6(1), February 2017.

3. Gungor B, Yagci FC, Gursel I, Gursel M. “Forging of a Potent Vaccine Adjuvant: CpG ODN/Cationic Peptide Nanorings”. Oncoimmunology, 3;3(7), July 2014.

4. Gungor B*, Yagci FC*, Tincer G, Bayyurt B, Alpdundar E, Yildiz S, Ozcan M, Gursel I, Gursel M. “CpG ODN nanorings induce IFNα from plasmocytoid dendritic cells and demonstrate potent vaccine adjuvant activity”. Sci Transl Med. 7;6 (235):235ra61, May 2014.

* These authors contributed equally to this work.

5. Osmanagaoglu O, Kıran F, Yagci FC, Gursel I. “Immunomodulatory function and in vivo properties of Pediococcus pentosaceus OZF, a promising probiotic strain.” Ann Microbiol DOI 10.1007/s13213-012-0590-9, December 2012.

6. Tincer G, Yerlikaya S, Yagci FC, Kahraman T, Atanur OM, Erbatur O, Gursel I. “Immunostimulatory Activity of Polysaccharide-Poly(I:C) Nanoparticles.” Biomaterials. 2011 Jun;32(18):4275-82, June 2011.

7. Yagci FC, Aslan O, Gursel M, Tincer G, Ozdamar Y, Karatepe K, Akcali CK, Gursel I. “Mammalian Telomeric DNA Suppresses Endotoxin Induced Uveitis”. J Biol Chem. 10;285(37):28806-11, September 2010.

Lipozomal Vaccine Adjuvant
(For Cloven Hooved Animals)

DESCRIPTION

Foot and Mouth Disease (FMD) is a highly contagious, outbreak causing viral disease that effects cloven-hoofed animals. The causative agent is a small RNA virus, picornavirus, with 7 serotypes. FMDV is a highly variable virus even there are variations within serotypes. The virus is mainly controlled by vaccination. Oligonucleotide containing unmethylated CpG motifs is a novel adjuvant that triggers the innate immune by Toll like receptor 9 (TLR9). Liposomal FMD vaccine is a ready to use vaccine containing lipid vesicles encapsulating oligonucleotide containing unmethylated CpG motifs and FMD serotype O antigen. Liposomal FMD vaccine is more effective than vaccines containing inactivated virus, which has some limitations such as providing short-term immune response. Liposomes, lipid bilayer vesicles, enhance biostability of entrapped molecules and act as a depot, therefore, decreases the antigen and adjuvant amount in vaccine. Also, liposomal vaccine provides long lasting protection against FMD, so higher protective immune response is developed with lower amount of antigen and adjuvant with only 2 times administration and is observed even in the first 2 weeks post-administration.

Nucleic Acid Based
Chicken Prophylactic Agent

DESCRIPTION

Nucleic Acid Based Chicken Prophylactic Agent (NABCPA) is an immunostimulatory prophylactic agent consists of synthetic unmethylated CpG motif containing single stranded DNA molecules with phosphodiester/phosphorothioate backbone structures. CpG ODN initiates signaling cascade through engagement of endosomal TLR21 and subsequently multiple immune cells are either directly or indirectly co-stimulated by the action of TLR21 mediated immune activation. CpG ODN stimulates innate immune responses of human and a variety of species including mice, sheep, cats, dogs, fish, horses and chicken. These responses can vary from species to species.
NABCPA contains CpG ODN sequences that confer optimal immune protection in chicken.
Unlike other immunomodulatory agents, NABCPA does not need any extra preparation steps such as vortexing, heating, homogenizing, sonicating and confers a ready to use prophylactic agent that can be easily prepared upon solving within PBS or Hanks buffer (pH:7.2-7.6).

TLR9L Adjuvant
(for mouse)

DESCRIPTION

The TLRL adjuvant consists of single stranded immunostimulatory sequences containing CpG motifs mimicking bacterial DNA (bDNA). Since immune cells evolved to recognize bacterial DNA and mount response against it, CpG DNA can trigger immune cells to initiate pro-inflammatory cascades. Therefore, CpG DNA recognition results in rapid and strong increase in co-stimulatory signals, and, when applied with an antigen, CpG DNA behaves as an excellent immune adjuvant to produce high titers of antigen-specific antibodies. Formulation of CpG adjuvant with an intended antigen is simple.
TLR9L-001 sequences are designed and optimized specifically to activate the immune system cells of mice.

TLR9L Adjuvant
(for bovine)

DESCRIPTION

The TLRL adjuvant consists of single stranded immunostimulatory sequences containing CpG motifs mimicking bacterial DNA (bDNA). Since immune cells evolved to recognize bacterial DNA and mount response against it, CpG DNA can trigger immune cells to initiate pro-inflammatory cascades. Therefore, CpG DNA recognition results in rapid and strong increase in co-stimulatory signals, and, when applied with an antigen, CpG DNA behaves as an excellent immune adjuvant to produce high titers of antigen-specific antibodies. Formulation of CpG adjuvant with an intended antigen is simple.
TLR9L-002 sequences are designed and optimized specifically to activate the immune system cells of bovine.

TLR21L Adjuvant
(for chicken)

DESCRIPTION

ABOUT US

SCIENCE

PIPELINE

CONTACT INFORMATION

LEAVE US A MESSAGE